Skip to Content
Morningstar

Teva Pharmaceutical Industries Ltd TEVA

Morningstar Rating
Unlock
Stock XTAE Rating as of
—
View Full Chart
As of Delayed Price
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
TEVA is trading within a range we consider fairly valued.
Price
ILS 61.08
Fair Value
ILS 22.19
Uncertainty
High
1-Star Price
ILS 33.84
5-Star Price
ILS 22.65
Economic Moat
Rrv
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TEVA is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
—
Day Range
—–—
52-Week Range
—–—
Bid/Ask
— / —
Market Cap
—
Volume/Avg
— / —

Key Statistics

Price/Earnings (Normalized)
6.21
Price/Sales
1.15
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Large Value
Total Number of Employees
37,851
Website
https://www.tevapharm.com

Competitors

Valuation

View More
Metric
TEVA
VTRS
RDY
Price/Earnings (Normalized)
 6.213.9018.37
Price/Book Value
 2.470.663.36
Price/Sales
 1.150.873.37
Price/Cash Flow
 11.524.0214.87
Price/Earnings
TEVA
VTRS
RDY

Financial Strength

Metric
TEVA
VTRS
RDY
Quick Ratio
 0.540.671.80
Current Ratio
 1.021.672.55
Interest Coverage
 0.391.3546.52
Quick Ratio
TEVA
VTRS
RDY

Profitability

Metric
TEVA
VTRS
RDY
Return on Assets (Normalized)
 6.03%7.07%15.57%
Return on Equity (Normalized)
 35.36%16.57%21.70%
Return on Invested Capital (Normalized)
 12.54%9.85%20.10%
Return on Assets
TEVA
VTRS
RDY
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class ANkjkvchxqHwrk$79.4 Bil
MKKGY
Merck KGaA ADRPnhfbcljfgDlkpg$79.0 Bil
HLN
Haleon PLC ADRNxfqtfcvhMpqyv$38.5 Bil
VTRS
Viatris IncNjkmfjfFjvs$13.1 Bil
RDY
Dr Reddy's Laboratories Ltd ADRJjbmjgllSgyg$11.7 Bil
CTLT
Catalent IncTzmthhjkBllxpj$10.0 Bil
CURLF
Curaleaf Holdings IncVdxbmntncMhhzm$4.2 Bil
PRGO
Perrigo Co PLCCbzyqvpckGyfgd$4.1 Bil
PBH
Prestige Consumer Healthcare IncRwdwdtcgCrrct$3.2 Bil
GTBIF
Green Thumb Industries IncRgvcqhznZpq$3.1 Bil

Sponsor Center